BIORPHEN (phenylephrine hydrochloride) by Dr. Reddy's Laboratories is α-1 adrenergic receptor agonist. First approved in 2019.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
BIORPHEN is an intravenous solution of phenylephrine hydrochloride, an α-1 adrenergic receptor agonist approved in October 2019. It is used to treat hypotension in acute care settings by increasing peripheral vascular resistance and blood pressure. The drug is indicated for patients requiring rapid hemodynamic support in hospital or critical care environments.
Product is at peak lifecycle stage with low Part B ASP ($0.163), indicating mature market positioning with limited pricing power and likely stable but resource-constrained team investment.
α-1 adrenergic receptor agonist.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu
Study to Find Out Whether Participants With a History of Stuffy Nose Due to Allergic Reactions in the Nose Would Intend to Buy Drug Phenylephrine Hydrochloride Extended Release Tablets After Receiving it Once in This Study
Safety of Phenylephrine Hydrochloride, Acetaminophen, Dimethindene Maleate Compared to Phenylephrine Hydrochloride Alone in Healthy Volunteers
Consumer Preference Study of Two Formulations of Phenylephrine Hydrochloride (Study CL2008-15)(P07530)(COMPLETED)
Worked on BIORPHEN at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on BIORPHEN offers stable, operational-focused career opportunities in a mature acute-care product with low clinical development activity. Roles emphasize hospital relationships, supply reliability, and safety monitoring rather than launch strategy or indication expansion, suiting professionals seeking established product management experience.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo